Imagion Biosystems Appoints Geoff Hollis as CFO

Imagion Biosystems Appoints Geoff Hollis as CFO

Imagion Biosystems has appointed Geoff Hollis as Chief Financial Officer. The appointment strengthens the Company’s management and leadership team as the Company moves into its next phase of growth to develop and commercialize its medical device technology to non-invasively detect cancer.

Geoff, based in Melbourne, takes up his position as Imagion CFO on 1 December 2020.

Geoff has served as the Chief Financial Officer for multiple ASX listed companies, including Lifestyle Communities where he played a key role in cash management and financing to facilitate rapid growth, reaching the ASX300 and creating significant shareholder value. Geoff’s career in finance began with 10 years at Pitcher Partners a top ten national accounting and financial advisory firm.

Imagion’s executive chairman and CEO, Bob Proulx, said Geoff is a welcome addition to Imagion’s executive management team. Being based in Australia, Geoff will be well positioned to assist with the Company’s developing business interests in Australia and will be closer to the Company’s investors and the capital markets to facilitate investor relations.

“We look forward to having Geoff aboard as the Company moves through its next growth phase and as we plan to advance the business beyond our upcoming MagSenseTM HER2 Phase I study for metastatic breast cancer,” Mr Proulx said.

“Geoff has had great experience in corporate transformation, growth strategies, capital raising, capital management, attracting institutional investors and general investor relations. We expect that will be of significant benefit to Imagion as we enter an exciting phase of our business and work to maximise shareholder value.”

Geoff replaces Brian Conn, who served as Imagion’s part-time CFO since 2017 and who left Imagion in August to take up a full-time CFO position with another of his clients.

Related Articles

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.